Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013)

Vericel's (VCEL) quarterly Preferred Stock Liabilities came in at $42.9 million in Q2 2013, up 13.76% year-on-year from $37.7 million in Q2 2012, and little changed quarter-over-quarter from $42.9 million in Q1 2013.

Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends

Vericel has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $42.9 million for Q2 2013.

  • Preferred Stock Liabilities for Q2 2013 came in at $42.9 million, up 13.76% year-over-year; the trailing twelve-month figure through Jun 2013 was $42.9 million (up 13.76% YoY), and the FY2012 annual result was $41.6 million, changed N/A from the prior year.
  • Preferred Stock Liabilities came in at $42.9 million for Q2 2013 at Vericel, roughly flat from $42.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $42.9 million in Q1 2013 to a low of $37.7 million in Q2 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Vericel 2.04 Bn 1.90 Bn 49.27 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2013 42.88 Mn
Mar 31, 2013 42.88 Mn
Dec 31, 2012 41.61 Mn
Sep 30, 2012 40.36 Mn
Jun 30, 2012 37.69 Mn